Anti-Aging
Potential Benefits of GHK-Cu Peptide Italy: Overview GHK-Cu, or glycyl-L-histidyl-L-lysine copper, is a naturally occurring copper-binding peptide found in human plasma, saliva and urine. Research
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. The immune system attacks myelin, damaging nerve fibers and disrupting communication between the brain and body.
This damage leads to symptoms such as muscle weakness, poor coordination, fatigue, and cognitive issues. Current treatments slow progression but do not repair nerve damage, so researchers continue to explore better solutions.
B7-33 peptide is an emerging research candidate. Scientists designed it as a synthetic analog of relaxin that activates the RXFP1 receptor, which regulates inflammation and tissue repair.
Studies show that B7-33 selectively activates ERK1/2 signaling and increases MMP-2 activity, mechanisms linked to reduced inflammation and improved tissue remodeling in preclinical models.
Because MS involves chronic inflammation and nerve damage, these effects suggest B7-33 may help regulate immune responses and limit damage in the central nervous system. However, research remains in early stages.
But how exactly does this peptide work? How could it help those living with MS? Let’s explore further.
Explore B7-33 Peptide from Direct SARMS Italy, a promising peptide that helps regulate immune responses and reduce neuroinflammation for improved MS management.
Multiple sclerosis (MS) occurs when the immune system attacks myelin, causing inflammation and nerve damage in the central nervous system.
B7-33 peptide may help by targeting these underlying processes. It acts as a selective agonist of the RXFP1 receptor, which regulates inflammation and tissue remodeling.
Research shows that B7-33 strongly activates ERK1/2 signaling, a pathway linked to reduced inflammation and cellular protection. It also increases MMP-2 activity, supporting tissue remodeling and reducing fibrosis in preclinical models.
Through these mechanisms, B7-33 may help modulate neuroinflammation and limit tissue damage in the CNS. However, current evidence comes only from laboratory and animal studies.
Explore Peptides Accessories at Direct SARMS Italy for all your reconstitution requirements.
B7-33 peptide regulates immune-related processes by activating the RXFP1 receptor rather than directly targeting specific immune cells. Research shows that it acts as a selective agonist and primarily activates ERK1/2 signaling, a pathway linked to reduced inflammation and cellular protection.
This selective signaling helps lower inflammatory responses and supports tissue-protective effects. Studies also show that B7-33 increases MMP-2 activity, which contributes to anti-fibrotic effects and improved tissue remodeling in preclinical models.
Because autoimmune diseases like MS involve chronic inflammation, these mechanisms suggest B7-33 may indirectly modulate immune activity by reducing inflammatory signaling. However, current evidence remains limited to laboratory and animal studies, and direct effects on immune cells, such as T cells, have not yet been confirmed.
The B7-33 peptide shows strong anti-fibrotic activity by activating the RXFP1 receptor. Research demonstrates that it stimulates ERK1/2 signaling and increases MMP-2 levels, which help break down excess collagen and reduce scar tissue formation.
Studies in multiple preclinical models show that B7-33 can reduce organ fibrosis and improve tissue structure, confirming its role in limiting abnormal extracellular matrix buildup.
In the context of MS, where chronic inflammation contributes to tissue damage and scarring in the central nervous system, these effects suggest B7-33 may help limit structural damage and support a healthier tissue environment. However, these findings come from non-MS preclinical studies, and direct effects in MS remain unconfirmed.
While B7-33 peptide shows great promise, it is not the only peptide under investigation for its potential benefits in MS research. Two other peptides — Thymosin Beta 4 and VIP peptide — are also being studied for their neuroprotective and immune-regulating effects. These peptides may work alongside B7-33 peptide to enhance MS treatment.
Thymosin Beta 4 is a peptide known for its role in tissue repair and wound healing.
Research shows that it can support nerve repair and myelin-related processes by promoting oligodendrogenesis, which helps generate myelin-producing cells and improve neurological function in preclinical models.
Because MS involves myelin damage and impaired nerve function, these effects suggest Thymosin Beta 4 may support neural repair. It also promotes cell migration and reduces inflammatory activity, which may further support recovery.
Through these effects, Thymosin Beta 4 may complement other peptides by supporting both tissue repair and inflammation control. However, current evidence remains limited to preclinical studies.
Discover Thymosin Beta 4 from Direct SARMS Italy, a peptide known for its tissue regeneration abilities and support for nerve repair and myelin regeneration.
VIP peptide (Vasoactive Intestinal Peptide) is a neuropeptide studied for its anti inflammatory and neuroprotective effects. Research shows that VIP can reduce inflammation in the brain and spinal cord and support neuronal survival under inflammatory conditions.
Studies also show that VIP can downregulate pro-inflammatory cytokines and reduce inflammatory activity, which helps protect the central nervous system from further damage.
In experimental MS models, VIP reduced disease severity and inflammation, suggesting it may help limit both inflammatory damage and neural injury.
Through these effects, VIP may complement other peptides by supporting neuroprotection and reducing inflammation. However, current evidence remains limited to pre clinical and experimental studies.
Check out VIP Peptide from Direct SARMS Italy, a neuroprotective peptide that helps reduce inflammation and protect nerve cells in the treatment of MS.
Research on peptides such as B7-33, Thymosin Beta 4, and VIP highlights a targeted approach to processes involved in MS, including inflammation and nerve damage.
Unlike traditional treatments that mainly manage symptoms, these peptides act on pathways linked to inflammation, tissue repair, and neuroprotection. For example, Thymosin Beta 4 promotes cell migration and angiogenesis and reduces inflammation, supporting tissue repair in preclinical models.
By reducing inflammatory signaling and supporting tissue remodeling, these peptides may offer a more targeted approach to limiting damage and supporting recovery. However, current evidence for all three peptides remains limited to laboratory and animal studies.
Research on B7-33, Thymosin Beta 4, and VIP peptides highlights a targeted approach to processes involved in MS, including inflammation, tissue damage, and repair. These peptides act on pathways such as RXFP1 signaling, oligodendrogenesis, and cytokine regulation, which are linked to reduced inflammation and improved tissue recovery in preclinical studies.
Unlike traditional treatments that mainly manage symptoms, these peptides show potential to influence underlying disease mechanisms by reducing inflammatory activity and supporting tissue repair. However, current evidence remains limited to laboratory and animal models.
As research progresses, these peptides may contribute to more targeted strategies for managing MS. While not yet approved for clinical use, they represent a developing area of research with potential to improve understanding of both inflammation and nerve repair in MS.
(1) Devarakonda T, Mauro AG, Guzman G, Hovsepian S, Cain C, Das A, Praveen P, Hossain MA, Salloum FN. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice. J Am Heart Assoc. 2020 Apr 21;9(8):e015748.
(2) Badawi AH, Siahaan TJ. Immune modulating peptides for the treatment and suppression of multiple sclerosis. Clin Immunol. 2012 Aug;144(2):127-38.
(3) Praveen P, Wang C, Handley TNG, Wu H, Samuel CS, Bathgate RAD, Hossain MA. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity. Int J Mol Sci. 2023 Apr 1;24(7):6616.
(4) Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012 Jan;12(1):37-51.
(5) Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J. 2003 May;17(8):944-6.
Choose Direct Sarms Italy for premium quality peptides nasal sprays, available online today!
What is the half-life of B7-33 peptide?
B7-33 peptide has a very short half-life in serum. In vitro studies show it degrades within approximately six minutes due to rapid enzymatic breakdown. This short stability limits systemic exposure. Research shows that chemical modifications, such as lipidation, can significantly extend its half-life without changing its biological activity.
How is B7-33 peptide different from relaxin?
B7-33 peptide is a single-chain derivative of human relaxin-2 and lacks the A-chain found in native relaxin. Unlike full-length relaxin, B7-33 activates RXFP1 in a biased manner. It favors ERK signaling while producing minimal cAMP activation, which changes its biological effects and improves safety and stability in research models.
What receptor does B7-33 peptide bind to in immune cells?
B7-33 peptide binds to the relaxin family peptide receptor 1, known as RXFP1. Research confirms RXFP1 as its primary target receptor. While RXFP1 expression is well documented in vascular and fibrotic tissues, immune cell signaling effects are believed to occur through the same receptor-mediated pathways.
Does B7-33 peptide affect fibrosis in the central nervous system?
Current research shows B7-33 peptide reduces fibrosis in cardiac, pulmonary, and biomaterial-associated tissue models. However, published studies have not directly demonstrated antifibrotic effects within central nervous system tissue. Any potential impact on CNS fibrosis remains theoretical and requires direct investigation in neurological or MS-specific research models.
Is B7-33 peptide rapidly degraded by peptidases in plasma?
Yes, B7-33 peptide undergoes rapid degradation in plasma. Its short in vitro half-life reflects high susceptibility to proteolytic enzymes. This rapid breakdown limits duration of action. Research demonstrates that structural modifications, including fatty-acid conjugation, can improve resistance to peptidase activity and enhance overall peptide stability.
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Italy Direct Sarms website is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
Potential Benefits of GHK-Cu Peptide Italy: Overview GHK-Cu, or glycyl-L-histidyl-L-lysine copper, is a naturally occurring copper-binding peptide found in human plasma, saliva and urine. Research
Discover the Difference between P-21 Vs Cerebrolysin Italy In the field of neurological research, the study of compounds with potential therapeutic benefits continues to expand.